(KRK) Krka d. d - Ratings and Ratios

Krka d.d. is a generic pharmaceutical company with a diversified product portfolio, including prescription pharmaceuticals, non-prescription products, and animal health products. The company operates globally, with a presence in various European regions and internationally. Its product offerings cater to a range of therapeutic areas, including cardiovascular, oncology, and pain relief, among others.

From a business perspective, Krkas strengths lie in its ability to develop, produce, and market a wide range of pharmaceutical products, allowing it to capitalize on opportunities in multiple markets. The companys geographic diversification and product breadth are key drivers of its revenue growth. With a Market Cap of 25.09B PLN and a P/E ratio of 16.49, Krkas valuation suggests a relatively stable and mature business. The companys Return on Equity (RoE) of 16.01% indicates a decent level of profitability.

To further evaluate Krkas performance, we can examine additional KPIs such as Revenue Growth Rate, Gross Margin, and Operating Margin. A high Revenue Growth Rate would indicate the companys ability to expand its market share, while a stable Gross Margin and Operating Margin would suggest efficient cost management and profitability. Assuming an average Revenue Growth Rate of 5-7% per annum, Krkas financials appear stable, with a potential for long-term growth driven by its diversified product portfolio and global presence.

From a valuation perspective, Krkas P/E ratio of 16.49 is relatively in line with industry averages, suggesting that the stock is fairly valued. However, a deeper analysis of the companys financials, including its Debt-to-Equity ratio and Interest Coverage, would provide a more comprehensive understanding of its financial health. With a Debt-to-Equity ratio potentially around 0.2-0.3, Krkas leverage appears manageable, allowing for flexibility in its capital structure.